Cheng-xin Gong
Advisor
BUSINESS MANAGEMENT
Alectos Therapeutics
United States of America
Biography
Dr. Cheng-Xin Gong received his medical degree from Xianning Medical College and an M.S. degree in Biochemistry from Tongji Medical University. Dr. Gong carried out postdoctoral research on the molecular mechanisms of Alzheimer’s disease. Dr. Gong is the Head and Director of the Brain Metabolism Laboratory at the New York State Institute for Basic Research in Developmental Disabilities. He is also an Adjunct Professor at the Graduate Center of the City University of New York. Dr. Gong investigates the molecular mechanisms of neurodegeneration in various brain diseases, especially in Alzheimer’s disease. He has made significant contributions to the understanding of the role of protein phosphatases in Alzheimer’s disease and other tauopathies. He was the first to demonstrate a down-regulation of protein phosphatase 2A in Alzheimer’s brains and its role in the abnormal hyperphosphorylation of tau and neurofibrillary degeneration. He has forwarded a hypothesis explaining the mechanism by which impaired brain glucose uptake contributes to neurodegeneration. Dr. Gong is a leading expert in Alzheimer’s disease, neurodegeneration, protein phosphorylation, protein glycosylation, and signal transduction. He has authored over 90 scientific publications. Dr. Cheng-Xin Gong received his medical degree from Xianning Medical College and an M.S. degree in Biochemistry from Tongji Medical University. Dr. Gong carried out postdoctoral research on the molecular mechanisms of Alzheimer’s disease. Dr. Gong is the Head and Director of the Brain Metabolism Laboratory at the New York State Institute for Basic Research in Developmental Disabilities. He is also an Adjunct Professor at the Graduate Center of the City University of New York. Dr. Gong investigates the molecular mechanisms of neurodegeneration in various brain diseases, especially in Alzheimer’s disease. He has made significant contributions to the understanding of the role of protein phosphatases in Alzheimer’s disease and other tauopathies. He was the first to demonstrate a down-regulation of protein phosphatase 2A in Alzheimer’s brains and its role in the abnormal hyperphosphorylation of tau and neurofibrillary degeneration. He has forwarded a hypothesis explaining the mechanism by which impaired brain glucose uptake contributes to neurodegeneration. Dr. Gong is a leading expert in Alzheimer’s disease, neurodegeneration, protein phosphorylation, protein glycosylation, and signal transduction. He has authored over 90 scientific publications.
Research Interest
BUSINESS MANAGEMENT
